Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-MUC1 CAR-pNK cells in MUC1+ solid tumors
NCT02839954Phase 2Unknown
- Sponsor
- PersonGen BioTherapeutics
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-muc1 car-pnk cells in hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), pancreatic carcinoma and 4 more, sponsored by PersonGen BioTherapeutics. Primary endpoint: Adverse events attributed to the administration of the anti-MUC1 CAR-pNK cells at 2 years. Status: unknown.
02
Drugs
anti-muc1 car-pnk cells
03
Conditions
hepatocellular carcinoma (HCC)non-small cell lung cancer (NSCLC)pancreatic carcinomatriple-negative breast cancer (TNBC)malignant glioma
Beyond the preview
Go deeper on NCT02839954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839954.